Researchers investigated arterial thromboembolism (ATE) in patients with multiple myeloma (MM) under modern therapy, finding a 2.7% incidence in the first year post-diagnosis. Analyzing Cleveland Clinic data from 2008-2018, it identifies acute ischemic stroke and myocardial infarction as primary ATE events, with advanced disease stage and other health conditions as risks. ATE correlates with lower 5-year overall survival rates. The study recommends thorough ATE risk assessment for MM patients and further research on ATE prophylaxis in high-risk individuals.

Reference: Chakraborty R, Rybicki L, Valent J, et al. Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. Blood Cancer J. 2021 Jun 25;11(6):121. doi: 10.1038/s41408-021-00513-4. PMID: 34172719; PMCID: PMC8233391.